Recombinant expression of receptor binding domains of all eight subtypes of botulinum neurotoxin type A for generation of antitoxins with broad reactivity.
Nga Quynh Pham, Tam Trang Mai, Tran Bao Anh Dang, Ly Huong Tran, Quynh Mai Vu, Chien Trong Nguyen, Anh Thi Phuong Tran, Tran Nhat Minh Dang, Van Anh Tran, Thinh Huy Tran, Van Khanh Tran, Hoa Quang Le
{"title":"Recombinant expression of receptor binding domains of all eight subtypes of botulinum neurotoxin type A for generation of antitoxins with broad reactivity.","authors":"Nga Quynh Pham, Tam Trang Mai, Tran Bao Anh Dang, Ly Huong Tran, Quynh Mai Vu, Chien Trong Nguyen, Anh Thi Phuong Tran, Tran Nhat Minh Dang, Van Anh Tran, Thinh Huy Tran, Van Khanh Tran, Hoa Quang Le","doi":"10.12688/f1000research.160607.1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Botulinum neurotoxin type A (BoNT/A) represents a major threat to global public health because of its most potent toxicity with the longest persistence. Several camelid single-domain antibodies (or VHHs) have been reported to exhibit high neutralizing activity against the receptor binding domain (H <sub>C</sub>) of the BoNT/A subtype used to generate them. However, it remains unclear if these VHHs can neutralize effectively H <sub>C</sub> of other BoNT/A subtypes. This study aimed to generate H <sub>C</sub> domains of all eight BoNT/A subtypes and to screen for VHHs with broad reactivity against these domains.</p><p><strong>Methods: </strong>H <sub>C</sub> domains of BoNT/A1-A8 were recombinantly produced in <i>Escherichia coli.</i> The <i>bont/H <sub>C</sub>A1</i> fragment was amplified from sludge sample and cloned into pET45b vector by Gibson assembly. Expression vectors for H <sub>C</sub> domains of BoNT/A2-A8 were derived from pET45b-H <sub>C</sub>A1 by site-directed mutagenesis and/or in-house gene synthesis. Similarly, VHHs were synthesized and cloned into pET22b vector. Recombinant protein were purified by Ni-NTA spin columns and analyzed by SDS-PAGE. ELISA was used to confirm the antigenicity of H <sub>C</sub> domains and to evaluate the reactivity of VHHs to these domains.</p><p><strong>Results: </strong>SDS-PAGE analysis and ELISA results with commercial polyclonal antibody demonstrated the H <sub>C</sub> domains of all eight BoNT/A subtypes were correctly produced. ELISA results using a VHH panel indicated that, apart from ciA-C2, a well-characterized VHH specific for H <sub>C</sub> of BoNT/A1, two new VHHs were found to recognize the H <sub>C</sub> domains of all BoNT/A subtypes, of which VHH-A3 displayed EC <sub>50</sub> values for these domains close to those of ciA-C2.</p><p><strong>Conclusion: </strong>This study provided a resource to comprehensively identify antitoxins conferring broad protection against BoNT/A.</p>","PeriodicalId":12260,"journal":{"name":"F1000Research","volume":"14 ","pages":"163"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880751/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"F1000Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12688/f1000research.160607.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Botulinum neurotoxin type A (BoNT/A) represents a major threat to global public health because of its most potent toxicity with the longest persistence. Several camelid single-domain antibodies (or VHHs) have been reported to exhibit high neutralizing activity against the receptor binding domain (H C) of the BoNT/A subtype used to generate them. However, it remains unclear if these VHHs can neutralize effectively H C of other BoNT/A subtypes. This study aimed to generate H C domains of all eight BoNT/A subtypes and to screen for VHHs with broad reactivity against these domains.
Methods: H C domains of BoNT/A1-A8 were recombinantly produced in Escherichia coli. The bont/H CA1 fragment was amplified from sludge sample and cloned into pET45b vector by Gibson assembly. Expression vectors for H C domains of BoNT/A2-A8 were derived from pET45b-H CA1 by site-directed mutagenesis and/or in-house gene synthesis. Similarly, VHHs were synthesized and cloned into pET22b vector. Recombinant protein were purified by Ni-NTA spin columns and analyzed by SDS-PAGE. ELISA was used to confirm the antigenicity of H C domains and to evaluate the reactivity of VHHs to these domains.
Results: SDS-PAGE analysis and ELISA results with commercial polyclonal antibody demonstrated the H C domains of all eight BoNT/A subtypes were correctly produced. ELISA results using a VHH panel indicated that, apart from ciA-C2, a well-characterized VHH specific for H C of BoNT/A1, two new VHHs were found to recognize the H C domains of all BoNT/A subtypes, of which VHH-A3 displayed EC 50 values for these domains close to those of ciA-C2.
Conclusion: This study provided a resource to comprehensively identify antitoxins conferring broad protection against BoNT/A.
F1000ResearchPharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
5.00
自引率
0.00%
发文量
1646
审稿时长
1 weeks
期刊介绍:
F1000Research publishes articles and other research outputs reporting basic scientific, scholarly, translational and clinical research across the physical and life sciences, engineering, medicine, social sciences and humanities. F1000Research is a scholarly publication platform set up for the scientific, scholarly and medical research community; each article has at least one author who is a qualified researcher, scholar or clinician actively working in their speciality and who has made a key contribution to the article. Articles must be original (not duplications). All research is suitable irrespective of the perceived level of interest or novelty; we welcome confirmatory and negative results, as well as null studies. F1000Research publishes different type of research, including clinical trials, systematic reviews, software tools, method articles, and many others. Reviews and Opinion articles providing a balanced and comprehensive overview of the latest discoveries in a particular field, or presenting a personal perspective on recent developments, are also welcome. See the full list of article types we accept for more information.